Comparison of cefaclor and amoxicillin for acute otitis media with effusion. 1981

E M Mandel, and C D Bluestone, and E I Cantekin, and S N Ghorbanian, and H E Rockette

A double-blind randomized clinical trial was conducted comparing cefaclor and amoxicillin for the treatment of acute otitis media with effusion in 110 children (150 ears). Each child underwent unilateral or bilateral tympanocentesis and then randomly received a 14-day course of either amoxicillin or cefaclor. Of 57 children in the cefaclor group, only 3 children (5.3%) had persistent or recurrent symptoms during the 14-day course of treatment, as compared to 5 of 53 children (9.4%) in the amoxicillin group, but this difference is not significant. After completion of the 14 days of therapy, 45 of 76 ears (59.2%) of the children in the cefaclor group were effusion-free, as compared to only 28 of 64 ears (43.7%) of the children in the amoxicillin group. When adjusted for age and race, this difference is statistically significant (p = .03). However, the difference between the effect of the two antimicrobials is not statistically significant in children. Cefaclor is a reasonable choice for antimicrobial therapy for acute otitis media with effusion, and from these study findings, it appears that cefaclor may be more effective than amoxicillin in resolving the middle ear effusion at the completion of 14-day therapy.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D010033 Otitis Media Inflammation of the MIDDLE EAR including the AUDITORY OSSICLES and the EUSTACHIAN TUBE. Middle Ear Inflammation,Inflammation, Middle Ear
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002433 Cefaclor Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN. 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, (6R-(6alpha,7beta(R*)))-,Ceclor,Cefaclor Anhydrous,Cefaclor Monohydrate,Keclor,Lilly 99638,S-6472,S 6472,S6472
D002506 Cephalexin A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms. 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))-,Cefalexin,Cephalexin Dihydride,Cephalexin Hemihydrate,Cephalexin Hydrochloride,Cephalexin Monohydrate,Cephalexin Monohydrochloride,Cephalexin Monohydrochloride, Monohydrate,Cephalexin, (6R-(6alpha,7alpha(R*)))-Isomer,Cephalexin, (6R-(6alpha,7beta(S*)))-Isomer,Cephalexin, (6R-(6alpha,7beta))-Isomer,Cephalexin, Monosodium Salt,Cephalexin, Monosodium Salt, (6R-(6alpha,7beta))-Isomer,Ceporexine,Palitrex
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic

Related Publications

E M Mandel, and C D Bluestone, and E I Cantekin, and S N Ghorbanian, and H E Rockette
June 1983, Bulletin of the New York Academy of Medicine,
E M Mandel, and C D Bluestone, and E I Cantekin, and S N Ghorbanian, and H E Rockette
March 1984, American journal of diseases of children (1960),
E M Mandel, and C D Bluestone, and E I Cantekin, and S N Ghorbanian, and H E Rockette
August 1998, Journal of chemotherapy (Florence, Italy),
E M Mandel, and C D Bluestone, and E I Cantekin, and S N Ghorbanian, and H E Rockette
March 1987, The Pediatric infectious disease journal,
E M Mandel, and C D Bluestone, and E I Cantekin, and S N Ghorbanian, and H E Rockette
May 1985, Pediatrics,
E M Mandel, and C D Bluestone, and E I Cantekin, and S N Ghorbanian, and H E Rockette
January 1985, Acta oto-laryngologica. Supplementum,
E M Mandel, and C D Bluestone, and E I Cantekin, and S N Ghorbanian, and H E Rockette
July 1998, The Pediatric infectious disease journal,
E M Mandel, and C D Bluestone, and E I Cantekin, and S N Ghorbanian, and H E Rockette
December 1989, American journal of diseases of children (1960),
E M Mandel, and C D Bluestone, and E I Cantekin, and S N Ghorbanian, and H E Rockette
October 1990, Southern medical journal,
E M Mandel, and C D Bluestone, and E I Cantekin, and S N Ghorbanian, and H E Rockette
November 1986, The Journal of pediatrics,
Copied contents to your clipboard!